Kairos Pharma Q2 FY26 net loss narrows to $1.39 million; revenue flat at no revenue - KAPA News | RalliesKairos Pharma Q2 FY26 net loss narrows to $1.39 million; revenue flat at no revenue
K
KAPA• Cash position and going-concern warning
- Cash and short-term investments totaled $2.63 million at June 30.
- The company flagged substantial doubt about going concern.
Q2 loss narrows while expenses edge lower
- Kairos Pharma posted a Q2 net loss of $1.39 million, narrowing from $1.42 million a year earlier.
- Operating loss improved to $1.42 million as total operating expenses edged down to $1.42 million.
- Research and development spending rose to $619,000, driven by a Phase 2 prostate cancer trial that began in 2024.
- General and administrative costs fell to $798,000; interest income slipped to $29,000.
PAAS
•
